Molecular Cancer Therapeutics: 10 (6)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther June 1 2011 10 (6) 915-915;

Therapeutic Discovery

Therapeutic Discovery | Free Article

Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance

Milos Dokmanovic, Yi Shen, Tabetha M. Bonacci, Dianne S. Hirsch and Wen Jin Wu

Mol Cancer Ther June 1 2011 10 (6) 917-928; DOI:10.1158/1535-7163.MCT-10-0980
Therapeutic Discovery

Overexpression of Mitotic Centromere–Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel

Anutosh Ganguly, Hailing Yang and Fernando Cabral

Mol Cancer Ther June 1 2011 10 (6) 929-937; DOI:10.1158/1535-7163.MCT-10-1109
Therapeutic Discovery

Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype

Kaijie He, Tong Xu and Amir Goldkorn

Mol Cancer Ther June 1 2011 10 (6) 938-948; DOI:10.1158/1535-7163.MCT-10-1120
Therapeutic Discovery

The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

Jenny E. Hernandez-Davies, Joan P. Zape, Elliot M. Landaw, Xiaolin Tan, Ajia Presnell, Diana Griffith, Michael C. Heinrich, Keith B. Glaser and Kathleen M. Sakamoto

Mol Cancer Ther June 1 2011 10 (6) 949-959; DOI:10.1158/1535-7163.MCT-10-0904
Therapeutic Discovery

B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation

Hao Liu, Christina Tekle, Yih-Wen Chen, Alexandr Kristian, Yuhua Zhao, Ming Zhou, Zixing Liu, Yan Ding, Bin Wang, Gunhild Mari Mælandsmo, Jahn Marthin Nesland, Oystein Fodstad and Ming Tan

Mol Cancer Ther June 1 2011 10 (6) 960-971; DOI:10.1158/1535-7163.MCT-11-0072
Therapeutic Discovery | Free Article

Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors

Eric A. Murphy, Bharat K. Majeti, Rajesh Mukthavaram, Lisette M. Acevedo, Leo A. Barnes and David A. Cheresh

Mol Cancer Ther June 1 2011 10 (6) 972-982; DOI:10.1158/1535-7163.MCT-10-0729
Therapeutic Discovery

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

Tom Van Maerken, Ali Rihani, Daniel Dreidax, Sarah De Clercq, Nurten Yigit, Jean-Christophe Marine, Frank Westermann, Anne De Paepe, Jo Vandesompele and Frank Speleman

Mol Cancer Ther June 1 2011 10 (6) 983-993; DOI:10.1158/1535-7163.MCT-10-1090
Therapeutic Discovery

A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos

Laura L. Vollmer, Maria Jiménez, Daniel P. Camarco, Wei Zhu, Hikmat N. Daghestani, Raghavan Balachandran, Celeste E. Reese, John S. Lazo, Neil A. Hukriede, Dennis P. Curran, Billy W. Day and Andreas Vogt

Mol Cancer Ther June 1 2011 10 (6) 994-1006; DOI:10.1158/1535-7163.MCT-10-1048

Preclinical Development

Preclinical Development

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

Anne-Christine Piguet, Bettina Saar, Ruslan Hlushchuk, Marie V. St-Pierre, Paul M.J. McSheehy, Vesna Radojevic, Maresa Afthinos, Luigi Terracciano, Valentin Djonov and Jean-François Dufour

Mol Cancer Ther June 1 2011 10 (6) 1007-1017; DOI:10.1158/1535-7163.MCT-10-0666
Preclinical Development | Free Article

The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells

Wei Fu, Le Ma, Baoky Chu, Xue Wang, Marilyn M. Bui, Jennifer Gemmer, Soner Altiok and W. Jackson Pledger

Mol Cancer Ther June 1 2011 10 (6) 1018-1027; DOI:10.1158/1535-7163.MCT-11-0167
Preclinical Development

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell, Jeffrey W. Tyner, Marc M. Loriaux, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Brian J. Druker, Tim Clackson and Victor M. Rivera

Mol Cancer Ther June 1 2011 10 (6) 1028-1035; DOI:10.1158/1535-7163.MCT-10-1044
Preclinical Development

Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma

Ron D. Jachimowicz, Giulio Fracasso, Paul J. Yazaki, Barbara E. Power, Peter Borchmann, Andreas Engert, Hinrich P. Hansen, Katrin S. Reiners, Madlener Marie, Elke Pogge von Strandmann and Achim Rothe

Mol Cancer Ther June 1 2011 10 (6) 1036-1045; DOI:10.1158/1535-7163.MCT-10-1093
Preclinical Development

ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance

Julie Millour, Natalia de Olano, Yoshiya Horimoto, Lara J. Monteiro, Julia K. Langer, Rosa Aligue, Nabil Hajji and Eric W.-F. Lam

Mol Cancer Ther June 1 2011 10 (6) 1046-1058; DOI:10.1158/1535-7163.MCT-11-0024
Preclinical Development

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

Victor M. Rivera, Rachel M. Squillace, David Miller, Lori Berk, Scott D. Wardwell, Yaoyu Ning, Roy Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang and Tim Clackson

Mol Cancer Ther June 1 2011 10 (6) 1059-1071; DOI:10.1158/1535-7163.MCT-10-0792
Preclinical Development

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan and David M. Goldenberg

Mol Cancer Ther June 1 2011 10 (6) 1072-1081; DOI:10.1158/1535-7163.MCT-11-0115
Preclinical Development

Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle

Hong Yao, Samuel S. Ng, Long-Fei Huo, Billy K. C. Chow, Zan Shen, Min Yang, Johnny Sze, Otis Ko, Ming Li, Alexander Yue, Li-Wei Lu, Xiu-Wu Bian, Hsiang-Fu Kung and Marie C. Lin

Mol Cancer Ther June 1 2011 10 (6) 1082-1092; DOI:10.1158/1535-7163.MCT-10-0717

Molecular Medicine in Practice

Molecular Medicine in Practice | Free Article

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Ana M. Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A. Barrera, Octavio Burgues, Ana M. Lluch, Huiqin Chen, Gabriel N. Hortobagyi, Gordon B. Mills and Funda Meric-Bernstam

Mol Cancer Ther June 1 2011 10 (6) 1093-1101; DOI:10.1158/1535-7163.MCT-10-1089
Molecular Medicine in Practice

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial

Monika E. Hegi, Annie-Claire Diserens, Pierre Bady, Yuta Kamoshima, Mathilde C. M. Kouwenhoven, Mauro Delorenzi, Wanyu L. Lambiv, Marie-France Hamou, Matthias S. Matter, Arend Koch, Frank L. Heppner, Yasuhiro Yonekawa, Adrian Merlo, Karl Frei, Luigi Mariani and Silvia Hofer

Mol Cancer Ther June 1 2011 10 (6) 1102-1112; DOI:10.1158/1535-7163.MCT-11-0048
Molecular Medicine in Practice

Hypoxia Induces Genomic DNA Demethylation through the Activation of HIF-1α and Transcriptional Upregulation of MAT2A in Hepatoma Cells

Quanyan Liu, Li Liu, Yuhong Zhao, Jin Zhang, Dongfeng Wang, Jiwei Chen, Yueming He, Jianguo Wu, Zhonglin Zhang and Zhisu Liu

Mol Cancer Ther June 1 2011 10 (6) 1113-1123; DOI:10.1158/1535-7163.MCT-10-1010

Main menu

User menu

Search

Table of Contents

Highlights

Therapeutic Discovery

Preclinical Development

Molecular Medicine in Practice

Issue Highlights

Jump to

Articles

Info for

About MCT